Clinical Trial Update: A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment [Phase 2]

View source ↗

Summary

Phase 2 study examining nivolumab plus brentuximab vedotin in patients aged 5-30 with relapsed or refractory classical Hodgkin lymphoma; the trial has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hodgkin Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-02-10